

Panion: Invitation to investor meeting in Stockholm, Friday 14th of December 2018, 12-13

Panion Animal Health AB invites all interested persons to an investor meeting at Mangolds offices, Engelbrektsplan 2, Stockholm on Friday the 14th of December 2018 from 12 - 13.

The occasion for the meeting is to provide information to current and new investors in relation to the share issue that runs from December 7, 2018 - December 21, 2018. The meeting is free and open for everyone.

Panion's CEO, Anja Holm, will present Panion's business plans and the ongoing research in gene therapy against epilepsy in dogs. The results that have been obtained

over the past two years of Panion's existence will be highlighted. The future development plans and expected milestones for the epilepsy product, and Panion's work on potential new in-licensing projects, will be discussed. The motive for the share issue is to secure the upcoming clinical pilot study in USA. There are currently different options available for future financing. By offering the current shareholders the opportunity to participate, we give the existing owners the same terms as may be offered to external investors.

To register for the investor meeting, please email to emissionstjanster@mangold.se

Panions VD, Anja Holm, kommer den 14 december hålla en investerarträff i Mangolds lokaler i Stockholm.

Anja kommer redogöra för Panions verksamhet och pågående forskning inom genterapi för behandling av epilepsiliknande tillstånd hos hundar.

För anmälan till investerarträffen vänligen maila till emissionstjanster@mangold.se

Datum: 14 december 2018

Tid: 12-13

Plats: Engelbrektsplan 2, Stockholm (Mangolds lokaler)

Teckningsperiod: 7 december 2018 - 21 december 2018

Teckningskurs: 1 SEK per aktie.

 For further information, please contact:

Anja E. H. Holm, CEO | +45-22 94 66 00
anja.holm@panion-animalhealth.com

Developing animal health - In Panion, we want to improve the quality of life for animals suffering from chronic diseases. We are convinced that gene therapy has promising prospects. Our aim is to develop and commercialize a gene therapy treatment for dogs with drug refractory epilepsy, based on CombiGene AB's technology and platform. Panion Animal Health AB is listed at Spotlight Stock Market.

Panion Animal Health AB

Frykholmmsgatan 11, 281 31 Hässleholm, Sweden
info@panion-animalhealth.com

[linkedin.com/company/panion-animalhealth](https://www.linkedin.com/company/panion-animalhealth) 

twitter.com/panionanihealth 

panion-animalhealth.com/newsletter 

panion-animalhealth.com 